|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAVAL, Quebec, Oct. 11, 2018 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018. In the studies, ALTRENO Lotion was shown to have significantly greater efficacy compared to vehicle in achieving treatment success, which was defined as at least a two-grade improvement from baseline in a global severity by Evaluator Global Severity Score (EGSS) and 'clear' or 'almost clear' skin.
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
PDUFA Date Set for February 25, 2019 LAVAL, Quebec , July 9, 2018 /CNW/ -- – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. ...
Why investors ought not to be dissuaded by an FDA rejection for a key Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) psoriasis cream.
Here's a company that may make a splash in the cannabis-based pharmaceuticals space, and it's not a producer like Canopy Growth Corp. (TSX:WEED)!
Learn how your own psychological makeup can provide valuable insights as to whether a stock like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is the right fit for you.
Find out what you can do to keep yourself from staying up at night wondering about what companies like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are doing with your hard-earned money.
Leverage can be both a gift and a curse. Find out what makes the cases of Dollarama Inc. (TSX:DOL) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) so different.
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
BlackBerry Ltd. (TSX:BB)(NYSE:BB) and Bombardier, Inc. (TSX:BBD.B) are two turnaround stocks that investors should consider as growth drivers for 2018 and beyond.
Aurora Cannabis Inc. (TSX:ACB) is a strong buy on the dip. Here's why the shareholder-dilutive acquisitions may not be as insidious as investors believe them to be.
NEW YORK, NY / ACCESSWIRE / June 23, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (VRX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980. The investigation concerns whether Valeant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
In 2015, Cindy Eckert (then Whitehead) made headlines after landing a billion-dollar deal for the company she co-founded, Sprout Pharmaceuticals, which developed female libido-boosting drug Addyi. Eckert co-founded Sprout Pharmaceuticals with her then-husband Robert Whitehead in 2011 to acquire a medication called flibanserin. With it, Sprout developed Addyi, dubbed "female Viagra," to treat hypoactive sexual desire disorder in premenopausal women ( 10 percent of all women suffer from HSDD).
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may have hit a stumbling block with one of the Significant Seven, but long-term investors should stay the course.
NEW YORK , June 19, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). ...